N‐terminal acetylation of α‐synuclein induces increased transient helical propensity and decreased aggregation rates in the intrinsically disordered monomer

The conformational properties of soluble α‐synuclein, the primary protein found in patients with Parkinson's disease, are thought to play a key role in the structural transition to amyloid fibrils. In this work, we report that recombinant 100% N‐terminal acetylated α‐synuclein purified under mild physiological conditions presents as a primarily monomeric protein, and that the N‐terminal acetyl group affects the transient secondary structure and fibril assembly rates of the protein. Residue‐specific NMR chemical shift analysis indicates substantial increase in transient helical propensity in the first 9 N‐terminal residues, as well as smaller long‐range changes in residues 28–31, 43–46, and 50–66: regions in which the three familial mutations currently known to be causative of early onset disease are found. In addition, we show that the N‐terminal acetylated protein forms fibrils that are morphologically similar to those formed from nonacetylated α‐synuclein, but that their growth rates are slower. Our results highlight that N‐terminal acetylation does not form significant numbers of dimers, tetramers, or higher molecular weight species, but does alter the conformational distributions of monomeric α‐synuclein species in regions known to be important in metal binding, in association with membranes, and in regions known to affect fibril formation rates.

[1]  P. Axelsen,et al.  The E46K mutation in alpha-synuclein increases amyloid fibril formation. , 2005, The Journal of biological chemistry.

[2]  Adam J. Trexler,et al.  N‐terminal acetylation is critical for forming α‐helical oligomer of α‐synuclein , 2012, Protein science : a publication of the Protein Society.

[3]  David S Wishart,et al.  RefDB: A database of uniformly referenced protein chemical shifts , 2003, Journal of biomolecular NMR.

[4]  J. Baum,et al.  Detection of transient interchain interactions in the intrinsically disordered protein alpha-synuclein by NMR paramagnetic relaxation enhancement. , 2010, Journal of the American Chemical Society.

[5]  S E Ide,et al.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. , 1997, Science.

[6]  Michael A. Geeves,et al.  Targeted Amino-Terminal Acetylation of Recombinant Proteins in E. coli , 2010, PloS one.

[7]  J. Hoenicka,et al.  The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia , 2004, Annals of neurology.

[8]  F. Sherman,et al.  Nα-terminal Acetylation of Eukaryotic Proteins* , 2000, The Journal of Biological Chemistry.

[9]  D. Eliezer,et al.  NMR mapping of copper binding sites in alpha-synuclein. , 2006, Biochimica et biophysica acta.

[10]  Oleg Jardetzky,et al.  Probability‐based protein secondary structure identification using combined NMR chemical‐shift data , 2002, Protein science : a publication of the Protein Society.

[11]  L. Bubacco,et al.  Interaction Between α-Synuclein and Metal Ions, Still Looking for a Role in the Pathogenesis of Parkinson’s Disease , 2009, NeuroMolecular Medicine.

[12]  M. Vendruscolo,et al.  The A53T mutation is key in defining the differences in the aggregation kinetics of human and mouse α-synuclein. , 2011, Journal of the American Chemical Society.

[13]  J. Marsh,et al.  Sensitivity of secondary structure propensities to sequence differences between α‐ and γ‐synuclein: Implications for fibrillation , 2006 .

[14]  R. Barbour,et al.  Phosphorylation of Ser-129 Is the Dominant Pathological Modification of α-Synuclein in Familial and Sporadic Lewy Body Disease* , 2006, Journal of Biological Chemistry.

[15]  R. L. Baldwin,et al.  Determination of free energies of N-capping in alpha-helices by modification of the Lifson-Roig helix-coil therapy to include N- and C-capping. , 1994, Biochemistry.

[16]  H. Lashuel,et al.  E46K Parkinson's-linked mutation enhances C-terminal-to-N-terminal contacts in alpha-synuclein. , 2009, Journal of molecular biology.

[17]  J. Marsh,et al.  Sensitivity of secondary structure propensities to sequence differences between alpha- and gamma-synuclein: implications for fibrillation. , 2006, Protein science : a publication of the Protein Society.

[18]  Wei Wang,et al.  A soluble α-synuclein construct forms a dynamic tetramer , 2011, Proceedings of the National Academy of Sciences.

[19]  C. Griesinger,et al.  Structural characterization of copper(II) binding to alpha-synuclein: Insights into the bioinorganic chemistry of Parkinson's disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Paul H. Axelsen,et al.  The E46K Mutation in α-Synuclein Increases Amyloid Fibril Formation* , 2005, Journal of Biological Chemistry.

[21]  Jennifer C. Lee,et al.  α-Synuclein: Stable compact and extended monomeric structures and pH dependence of dimer formation , 2004, Journal of the American Society for Mass Spectrometry.

[22]  Vladimir N Uversky,et al.  Biophysics of Parkinson's disease: structure and aggregation of alpha-synuclein. , 2009, Current protein & peptide science.

[23]  R. Krüger,et al.  Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. , 1998, Nature genetics.

[24]  S. Doglia,et al.  Compact conformations of α‐synuclein induced by alcohols and copper , 2011, Proteins.

[25]  V. Uversky,et al.  Characterization of intrinsically disordered proteins with electrospray ionization mass spectrometry: Conformational heterogeneity of α‐synuclein , 2009, Proteins.

[26]  Peter T. Lansbury,et al.  Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease , 1998, Nature Medicine.

[27]  T. Arnesen Towards a Functional Understanding of Protein N-Terminal Acetylation , 2011, PLoS biology.

[28]  J Q Trojanowski,et al.  Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. , 1998, The American journal of pathology.

[29]  Anders Wallin,et al.  Identification of Novel α-Synuclein Isoforms in Human Brain Tissue by using an Online NanoLC-ESI-FTICR-MS Method , 2011, Neurochemical Research.

[30]  R. L. Baldwin,et al.  Further studies of the helix dipole model: Effects of a free α‐NH3+ or α‐COO− group on helix stability , 1989 .

[31]  R. Aurora,et al.  Helix capping , 1998, Protein science : a publication of the Protein Society.

[32]  S. Radford,et al.  Elongated oligomers in β2-microglobulin amyloid assembly revealed by ion mobility spectrometry-mass spectrometry , 2010, Proceedings of the National Academy of Sciences.

[33]  D. Schwarzer,et al.  Simultaneous detection of protein phosphorylation and acetylation by high-resolution NMR spectroscopy. , 2010, Journal of the American Chemical Society.

[34]  R. L. Baldwin,et al.  Helix capping propensities in peptides parallel those in proteins. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[35]  R. L. Baldwin,et al.  Further studies of the helix dipole model: effects of a free alpha-NH3+ or alpha-COO- group on helix stability. , 1989, Proteins.

[36]  D. Eliezer,et al.  Residual structure, backbone dynamics, and interactions within the synuclein family. , 2007, Journal of molecular biology.

[37]  R. Crowther,et al.  α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies , 1998 .

[38]  D. Selkoe,et al.  α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation , 2011, Nature.

[39]  R A Crowther,et al.  alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Bernard Schneider,et al.  α-Synuclein in Central Nervous System and from Erythrocytes, Mammalian Cells, and Escherichia coli Exists Predominantly as Disordered Monomer* , 2012, The Journal of Biological Chemistry.

[41]  D. Eliezer,et al.  Residual Structure and Dynamics in Parkinson's Disease-associated Mutants of α-Synuclein* , 2001, The Journal of Biological Chemistry.

[42]  F. Sherman,et al.  N-terminal acetyltransferases and sequence requirements for N-terminal acetylation of eukaryotic proteins. , 2003, Journal of molecular biology.

[43]  C. Griesinger,et al.  Site-specific interactions of Cu(II) with alpha and beta-synuclein: bridging the molecular gap between metal binding and aggregation. , 2008, Journal of the American Chemical Society.

[44]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[45]  Carlo Camilloni,et al.  Determination of secondary structure populations in disordered states of proteins using nuclear magnetic resonance chemical shifts. , 2012, Biochemistry.